NO20091999L - MAPK/ERK kinase inhibitorer - Google Patents
MAPK/ERK kinase inhibitorerInfo
- Publication number
- NO20091999L NO20091999L NO20091999A NO20091999A NO20091999L NO 20091999 L NO20091999 L NO 20091999L NO 20091999 A NO20091999 A NO 20091999A NO 20091999 A NO20091999 A NO 20091999A NO 20091999 L NO20091999 L NO 20091999L
- Authority
- NO
- Norway
- Prior art keywords
- mapk
- kinase inhibitors
- erk kinase
- erk
- mek
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86256906P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/082138 WO2008140553A2 (en) | 2006-10-23 | 2007-10-22 | Mapk/erk kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091999L true NO20091999L (no) | 2009-07-06 |
Family
ID=39954277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091999A NO20091999L (no) | 2006-10-23 | 2009-05-22 | MAPK/ERK kinase inhibitorer |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7696218B2 (xx) |
| EP (1) | EP2091941B1 (xx) |
| JP (1) | JP5249939B2 (xx) |
| KR (1) | KR20090071666A (xx) |
| CN (1) | CN101563338A (xx) |
| AR (1) | AR063357A1 (xx) |
| AU (1) | AU2007353385A1 (xx) |
| BR (1) | BRPI0717374A2 (xx) |
| CA (1) | CA2667447A1 (xx) |
| CL (1) | CL2007003041A1 (xx) |
| CO (1) | CO6180442A2 (xx) |
| CR (1) | CR10818A (xx) |
| DO (1) | DOP2009000089A (xx) |
| EA (1) | EA200970407A1 (xx) |
| EC (1) | ECSP099354A (xx) |
| IL (1) | IL198254A0 (xx) |
| MA (1) | MA30889B1 (xx) |
| MX (1) | MX2009004269A (xx) |
| NO (1) | NO20091999L (xx) |
| NZ (1) | NZ577047A (xx) |
| PE (1) | PE20081468A1 (xx) |
| TN (1) | TN2009000151A1 (xx) |
| TW (1) | TW200831100A (xx) |
| WO (1) | WO2008140553A2 (xx) |
| ZA (1) | ZA200903274B (xx) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696218B2 (en) * | 2006-10-23 | 2010-04-13 | Takeda San Diego, Inc. | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| WO2009064675A1 (en) * | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| EP2321640B1 (en) * | 2008-08-21 | 2016-11-30 | Immunogenics LLC | Formulation for oral administration of proteins |
| US9199946B2 (en) * | 2012-04-03 | 2015-12-01 | Bristol-Myers Squibb Company | Pyrimidinone carboxamide inhibitors of endothelial lipase |
| WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
| DE102015117207A1 (de) | 2015-10-08 | 2017-04-13 | Silas Mehmet Aslan | Verfahren zur Herstellung von polythiophenhaltigen Fluiden |
| IL259810A (en) | 2018-06-04 | 2018-07-31 | Yeda Res & Dev | Mitogen-activated protein kinase kinase 7 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58152890A (ja) * | 1982-03-08 | 1983-09-10 | Takeda Chem Ind Ltd | イソキサゾロピリミジン誘導体 |
| US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
| AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4－碘苯氨基苯氧肟酸的氧合酯 |
| WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| DK1689233T3 (da) | 2003-11-19 | 2012-10-15 | Array Biopharma Inc | Bicykliske inhibitorer af MEK |
| US20070293544A1 (en) | 2004-11-24 | 2007-12-20 | Ulrich Abel | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders |
| US20060223807A1 (en) * | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| ES2333182T3 (es) | 2005-05-18 | 2010-02-17 | Array Biopharma, Inc. | Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas. |
| US7696218B2 (en) * | 2006-10-23 | 2010-04-13 | Takeda San Diego, Inc. | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| WO2009064675A1 (en) | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| US20090246198A1 (en) * | 2008-03-31 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
-
2007
- 2007-10-22 US US11/876,635 patent/US7696218B2/en active Active
- 2007-10-22 WO PCT/US2007/082138 patent/WO2008140553A2/en active Application Filing
- 2007-10-22 JP JP2009534802A patent/JP5249939B2/ja active Active
- 2007-10-22 CN CNA2007800471578A patent/CN101563338A/zh active Pending
- 2007-10-22 US US12/446,974 patent/US20100204471A1/en not_active Abandoned
- 2007-10-22 AU AU2007353385A patent/AU2007353385A1/en not_active Abandoned
- 2007-10-22 NZ NZ577047A patent/NZ577047A/en not_active IP Right Cessation
- 2007-10-22 KR KR1020097010570A patent/KR20090071666A/ko not_active Application Discontinuation
- 2007-10-22 CA CA002667447A patent/CA2667447A1/en not_active Abandoned
- 2007-10-22 EP EP07874225A patent/EP2091941B1/en active Active
- 2007-10-22 EA EA200970407A patent/EA200970407A1/ru unknown
- 2007-10-22 MX MX2009004269A patent/MX2009004269A/es active IP Right Grant
- 2007-10-22 BR BRPI0717374-1A patent/BRPI0717374A2/pt not_active IP Right Cessation
- 2007-10-22 ZA ZA200903274A patent/ZA200903274B/xx unknown
- 2007-10-23 AR ARP070104689A patent/AR063357A1/es not_active Application Discontinuation
- 2007-10-23 TW TW096139723A patent/TW200831100A/zh unknown
- 2007-10-23 PE PE2007001430A patent/PE20081468A1/es not_active Application Discontinuation
- 2007-10-23 CL CL200703041A patent/CL2007003041A1/es unknown
-
2009
- 2009-04-21 IL IL198254A patent/IL198254A0/en unknown
- 2009-04-22 TN TNP2009000151A patent/TN2009000151A1/fr unknown
- 2009-04-23 DO DO2009000089A patent/DOP2009000089A/es unknown
- 2009-05-13 MA MA31870A patent/MA30889B1/fr unknown
- 2009-05-21 EC EC2009009354A patent/ECSP099354A/es unknown
- 2009-05-21 CR CR10818A patent/CR10818A/es not_active Application Discontinuation
- 2009-05-22 CO CO09053035A patent/CO6180442A2/es not_active Application Discontinuation
- 2009-05-22 NO NO20091999A patent/NO20091999L/no not_active Application Discontinuation
-
2010
- 2010-01-05 US US12/652,570 patent/US7943626B2/en active Active
-
2011
- 2011-04-07 US US13/082,259 patent/US8088783B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080784L (no) | Histondeacetylaseinhibitorer | |
| NO20091999L (no) | MAPK/ERK kinase inhibitorer | |
| WO2008055236A3 (en) | Mapk/erk kinase inhibitors | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| MY146989A (en) | Kinase inhibitors | |
| WO2006105127A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
| TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
| WO2008115890A3 (en) | Mapk/erk kinase inhibitors | |
| WO2007028135A3 (en) | Imidazopyridine compounds | |
| WO2006066109A3 (en) | Hydroxysteroid dehydrogenase inhibitors | |
| WO2009146034A3 (en) | Mapk/erk kinase inhibitors and methods of use thereof | |
| TN2010000131A1 (en) | Polo-like kinase inhibitors | |
| NO20091817L (no) | Kinase inhibitorer | |
| AU2015200390A1 (en) | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | |
| WO2009156462A3 (en) | Organic compounds | |
| WO2007075847A3 (en) | Glucokinase activators | |
| WO2007061923A3 (en) | Glucokinase activators | |
| WO2007084390A3 (en) | Histone deacetylase inhibitors | |
| WO2007117995A3 (en) | Kinase inhibitors | |
| UA100190C2 (xx) | Інгібітори кіназ акт та p70-s6$ингибиторы киназ акт и p70-s6 | |
| DK1711177T3 (da) | 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer | |
| NO20084457L (no) | Tiazolidinderivater som P13 kinaseinhibitorer | |
| WO2007099171A3 (en) | Bicyclo-pyrazoles active as kinase inhibitors | |
| WO2008045834A3 (en) | Kinase inhibitors | |
| WO2009129401A8 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |